Table 1. Baseline characteristics of patients.

Characteristic	Surgery (n = 278)	Adjuvant chemotherapy (n = 394)	Neoadjuvant chemotherapy (n = 133)
Age, years     Mean (range)	48.8 (23–65)	48.9 (26–65)	49.3 (26–65)
BMI, kg/m2     Mean (SD)	22.55 (3.00)	22.60 (2.78)	23.27 (3.14)
Type of surgery
Breast-conserving	103 (37.0%)	152 (38.6%)	25 (18.8%)
Mastectomy	175 (63.0%)	242 (61.4%)	105 (78.9%)
Unknown	0	0	3* (2.3%)
Depth of tumor invasion (T)
Tis	144 (51.8%)	6 (1.5%)	0
T1	109 (39.2%)	260 (66.0%)	61 (45.9%)
T2	21 (7.6%)	118 (30.0%)	65 (48.9%)
T3-T4	1 (0.4%)	4 (1.0%)	7 (5.2%)
Unknown	3# (1.0%)	6# (1.5%)	0
Lymph node metastasis (N)
N0	267 (96.0%)	273 (69.3%)	21 (15.8%)
N1	11 (4.0%)	100 (25.4%)	94 (70.7%)
N2-N3	0	21 (5.3%)	18 (13.5%)
ER status
Negative	52 (18.7%)	107 (27.2%)	53 (39.8%)
Positive	225 (80.9%)	279 (70.8%)	77 (57.9%)
Unknown	1 (0.4%)	8 (2.0%)	3 (2.3%)
PR status
Negative	51 (18.3%)	135 (34.3%)	69 (51.9%)
Positive	226 (81.3%)	252 (63.9%)	61 (45.9%)
Unknown	1 (0.4%)	7 (1.8%)	3 (2.2%)
HER-2 status
Negative	189 (68.0%)	258 (65.5%)	85 (63.9%)
Positive	61 (21.9%)	134 (34.0%)	47 (35.3%)
Unknown	28& (10.1%)	2# (0.5%)	1# (0.8%)
Ki-67 status
<20%	167 (60.1%)	112 (28.4%)	58 (43.6%)
≥20%	94 (33.8%)	260 (66.0%)	64 (48.1%)
Unknown	17 (6.1%)	22 (5.6%)	11 (8.3%)
Endocrine therapy
Yes	228 (82.0%)	285 (72.3%)	82 (61.7%)
No	50 (18.0%)	109 (27.7%)	51 (38.3%)
Radiation therapy
Yes	101 (36.3%)	213 (54.1%)	107 (80.5%)
No	177 (63.7%)	181 (45.9%)	26 (19.5%)

BMI: Body mass index; SD: Standard deviation; ER: Estrogen receptor; PR: Progesterone receptor

*: Had not received the operation for breast cancer at the Second Affiliated Hospital of Zhejiang University after neoadjuvant chemotherapy.

^#: No information was available.

^&: No further FISH test in many patients with intraductal carcinoma.